2-phenyl-1-(N,N-dimethylamino)methyl-cyclopropane | 624732-11-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-phenyl-1-(N,N-dimethylamino)methyl-cyclopropane
• 英文别名: N,N-dimethyl-1-[(1R,2R)-2-phenylcyclopropyl]methanamine
• CAS: 624732-11-2
• 化学式: C₁₂H₁₇N
• 分子量: 175.274
• InChiKey: VMVOTHRTTGEMKL-RYUDHWBXSA-N

物化性质

• 沸点：
  243.5±9.0 °C(Predicted)
• 密度：
  0.980±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (1R,2R)-2-{methyl-[(E)-3-phenyl-2-propenyl]amino}-1-phenylpropan-1-ol 在 diethylzinc 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 反应 195.83h， 生成 2-phenyl-1-(N,N-dimethylamino)methyl-cyclopropane
  参考文献：
  名称：

  Highly Diastereoselective Simmons−Smith Cyclopropanation of Allylic Amines

  摘要：

  Cyclopropanation of allylic tertiary amines using the Simmons-Smith reagent has been achieved by employing chelating groups in close proximity to the amine. The chelating groups promote cyclopropa nation at the expense of N-ylide formation. Using pseudoephedrine as the chelating group, high diastereoselectivity is observed.

  DOI：

  10.1021/ol035713b

文献信息

• Heterocyclic compounds and methods of their use
  申请人：NOVARTIS AG

  公开号：US10370388B2

  公开（公告）日：2019-08-06

  The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及可用于拮抗血管紧张素 II 2 型（AT2）受体的杂环化合物。更具体地说，本发明涉及吡咯烷和氮杂环丁烷化合物、含有它们的组合物及其在治疗或预防与 AT2 受体功能有关的紊乱或疾病的方法中的用途，这些紊乱或疾病包括神经性疼痛、炎症性疼痛、与神经元超敏性有关的病症、神经传导速度受损、细胞增殖紊乱、与骨吸收和骨形成失衡有关的紊乱以及与神经再生异常有关的紊乱。
• Trifluoromethylated amino alcohol as chiral auxiliary for highly diastereoselective and fast Simmons–Smith cyclopropanation of allylic amine
  作者：Toshimasa Katagiri、Naomi Iguchi、Tomomi Kawate、Satoshi Takahashi、Kenji Uneyama

  DOI：10.1016/j.tetasy.2006.04.031

  日期：2006.4

  Three advantages of a trifluoromethylated amino alcohol auxiliary in the Simmons-Smith cyclopropanation of allylic amines are described. The trifluoromethylated amino alcohol auxiliary reduces unwanted side reactions induced by its acidic, and thus less nucleophilic, hydroxy group. The auxiliary accelerated the reaction rate by its electron-withdrawing effect, and promoted the reaction with excellent diastereoselectivity. (c) 2006 Elsevier Ltd. All rights reserved.
• Heterocyclic Compounds and Methods of Their Use
  申请人：Spinifex Pharmaceuticals Pty Ltd

  公开号：US20140378430A1

  公开（公告）日：2014-12-25

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT 2 ) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT 2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
• HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE
  申请人：NOVARTIS AG

  公开号：US20170145032A1

  公开（公告）日：2017-05-25

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT 2 ) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT 2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
• US9624243B2
  申请人：——

  公开号：US9624243B2

  公开（公告）日：2017-04-18